(Ϫ/Ϫ) mice compared with wild-type mice, an observation that was accompanied by decreased hippocampal levels of mature brain-derived neurotrophic factor. Microinjecting the BDNF scavenger TrkB-Fc into the right ventricle before each PTZ treatment significantly suppressed the development of kindling in wild-type mice, whereas no effect was observed in MMP-9 (Ϫ/Ϫ) mice. On the other hand, bilateral injections of pro-BDNF into the hippocampal dentate gyrus significantly enhanced kindling in wild-type mice but not MMP-9 (Ϫ/Ϫ) mice. These findings suggest that MMP-9 is involved in the progression of behavioral phenotypes in kindled mice because of conversion of pro-BDNF to mature BDNF in the hippocampus.
Introduction
Seizures cause brain injury via a number of mechanisms, potentially contributing to neurologic and cognitive deficits in epilepsy patients. Although seizures induce neuronal death in some situations, they also can produce nonlethal pathophysiologic effects on neuronal structures and functions (Zeng et al., 2007) . Kindling is an experimental epilepsy model in which repeated electrical or chemical stimulation of certain forebrain structures triggers progressively more intense electroencephalographic and behavioral seizure activity (Goddard et al., 1969; Racine, 1972) . Once established, kindling results in a permanent state of seizure susceptibility, which may manifest as spontaneous epileptiform seizures (Pinel and Rovner, 1978) . Kindling has recently been shown to induce a variety of permanent structural changes in the brain, including sprouting of the mossy fiber pathway that originates from hippocampal dentate gyrus (DG) granule cells (Sutula et al., 1988; Cavazos et al., 1991) and neuronal loss in the hippocampus (Cavazos et al., 1994) .
Matrix metalloproteinases (MMPs) function to remodel the pericellular environment, primarily through cleavage of extracellular matrix proteins and cell surface components (Yong et al., 2001 ). Gelatinases (MMP-2 and MMP-9), for example, cleave the cell adhesion proteins collagen IV and V, laminin, and chondroi-tin sulfate proteoglycan (Yong et al., 2001) . Of clinical relevance, MMP-9 has been implicated in amyloid-induced cognitive impairment and neurotoxicity (Mizoguchi et al., 2009) , cerebral ischemia, kainate-induced neuronal injury (Szklarczyk et al., 2002) , hippocampal long-term potentiation and memory (Nagy et al., 2006) , and methamphetamine dependence (Mizoguchi et al., 2007a (Mizoguchi et al., , 2007b . Thus, MMP-9 is involved in neuronal activitydependent synaptic plasticity and cell death in the brain.
Interestingly, serum MMP-9 levels and the ratio of MMP-9 to tissue inhibitor of metalloproteinase-1 are elevated in children with various febrile seizures and convulsive status epilepticus (Suenaga et al., 2008) . Moreover, expression of MMP-9 mRNA increases in response to neuronal depolarization in the rat hippocampus (Rylski et al., 2009) . After seizure, MMP-9 mRNA is transported to dendrites and synapses in the hippocampal DG of kainic acid-treated rats . Jourquin et al. (2003) used organotypic cultures to demonstrate increased release and activity of MMP-9 after stimulation with neurotoxic kainate and reduced neuronal cell death following MMP-9 inhibition. Although MMP-9 is expressed in response to neural activity in some models of epileptogenesis (Wilczynski et al., 2008; Kim et al., 2009; Takács et al., 2010) , the pathophysiologic and etiologic roles of this metalloproteinase, including potential molecular targets, during kindling seizure development have not been elucidated. In the present study, we used MMP-9 homozygous knock-out (Ϫ/Ϫ) )mice to investigate the role of MMP-9 in kindling induced by pentylenetetrazole (PTZ).
Materials and Methods
Animals. Male ICR mice (7-8 weeks old; weighing 40 Ϯ 5 g at the beginning of the experiments) were obtained from CLEA Japan. We also used (Ϫ/Ϫ) (Jackson Laboratory), MMP-2 homozygous knock-out (MMP-2 (Ϫ/Ϫ) ) (Itoh et al., 1997) , and wild-type (C57BL/6J) mice (9 -14 weeks old). The mutant mice were backcrossed into the C57BL/6J strain Ͼ13 times. Mutant and wild-type mice used in the present study were littermates, and only male mice were used in the behavioral tests. The animals were housed in plastic cages and kept in a regulated environment (23 Ϯ 1°C; 50 Ϯ 5% humidity) with a 12 h light-dark cycle (lights on at 9:00 A.M.). Food (CE-2, CLEA Japan) and tap water were available ad libitum. All experiments were performed in accordance with the Guidelines for Animal Experiments of Kanazawa University and Nagoya University Graduate School of Medicine, the Guiding Principles for the Care and Use of Laboratory Animals approved by the Japanese Pharmacological Society, and the United States National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Drugs. PTZ (Sigma-Aldrich) and dizocilpine hydrogen maleate (MK-801; Sigma-Aldrich) were dissolved in saline. Diazepam (Sigma-Aldrich) was suspended in 1% carboxymethyl cellulose (CMC).
Seizure observation and kindling procedure. PTZ was administered intraperitoneally at a dose of 20 -60 mg/kg. We used the PTZ-induced kindling model described by Schröder et al. (1993) and Becker et al. (1995) . ICR mice were intraperitoneally injected with PTZ (40 mg/kg) once every 48 h for at least nine total injections, and mice showing more than three consecutive Stage 4 seizures were used as kindled mice. Because of their different sensitivity to PTZ, C57BL/6J mice were injected with PTZ at a dose of 35 mg/kg to induce kindling. The PTZ dose was reduced to 25 mg/kg for mice in which guide cannulae had been implanted for intraventricular or intrahippocampal microinjections (see below). Control animals were injected with saline. Diazepam (1 mg/kg) or MK-801 (0.1 mg/kg) was administered intraperitoneally 30 min before PTZ injection. We examined seizure events during a 20 min observation period after each stimulation.
The seizure intensity was scored as follows (Schröder et al., 1993; Becker et al., 1995, modified Microinjection of tropomyosin-related kinase B-Fc and pro-brainderived neurotrophic factor. Mice were anesthetized with sodium pentobarbital and placed in a stereotaxic apparatus. Metal guide cannulae (inner diameter, 0.4 mm; outer diameter, 0.5 mm) were implanted stereotaxically into the right ventricle (anteroposterior Ϫ0.3; mediolateral ϩ1.0 from the bregma; dorsoventral Ϫ2.2 from the skull) for injections of the brain-derived neurotrophic factor (BDNF) scavenger tropomyosinrelated kinase B-Fc (TrkB-Fc), and bilaterally into the DG of the hippocampus (anteroposterior Ϫ2.2; mediolateral Ϯ1.2 from the bregma; dorsoventral Ϫ1.8 from the skull) for injections of pro-BDNF. The guide cannula was mounted on the skull with dental cement, and a dummy cannula was left in place throughout the experiment. Mice were allowed to recover for 4 d. On Day 5, a 28-G infusion cannula was inserted through the guide cannula until it protruded 0.5 mm beyond the inner end. TrkB-Fc (R&D Systems) or IgG 1 -Fc (R&D Systems) was microinjected at a dose of 50 ng/l and a rate of 1 l/min (final volume, 2 l) according to previous reports (Yajima et al., 2005; Zhou et al., 2010) with minor modifications. pro-BDNF (50 ng/l; #B-240, Alomone Labs) or the vehicle PBS was bilaterally microinjected at a rate of 1 l/min (final volume, 1 l) according to the previous studies (Shirayama et al., 2002; Yajima et al., 2005) with minor modifications. After the injection, the cannula was left in place for 1 min to allow the solution to diffuse. PTZ (25 mg/kg) was injected 30 min after microinjection of the drugs.
Conditioned fear memory test. Contextual fear conditioning tests were performed based on previous reports (Mizoguchi et al., 2010) with minor modifications. Freezing behavior, during which the mouse's head, arms, and legs did not move, was timed using a stopwatch. To measure the basal freezing response (preconditioning phase), mice were individually placed in a transparent Plexiglas conditioning cage (30 ϫ 30 ϫ 35 cm) for 2 min. For training (conditioning phase), mice were placed in the con- ditioning cage and subjected to the conditioned stimulus (15 s tone at 80 dB). During the last 5 s of the tone stimulus, a 0.8 mA foot shock was delivered as the unconditioned stimulus via a shock generator (BrainScience Idea). This procedure was repeated four times with 15 s intervals. Contextual tests were performed 1 d after fear conditioning. For the contextual test, mice were placed in the conditioning cage and the freezing response was measured for 2 min in the absence of the conditioned stimulus.
Quantitative analysis of BDNF mRNA. After the final administration of PTZ, mice were decapitated. A region of the brain that included the hippocampus was dissected from freshly perfused brains, immediately frozen, and stored at Ϫ80°C until the assay. All dissections were performed using brain matrix (BrainScience Idea) and based on an anatomic atlas (Franklin and Paxinos, 1997) .
Sequences of the forward and reverse primers used for the real-time PCRs are as follows: mouse BDNF, 5Ј-TAAATGAAGTTTATACAGTACAGTGG TTCTACA-3Ј and 5Ј-AGTTGTGCGCAAATGACTGTTT-3Ј; and mouse GAPDH,5Ј-TGTCAAGCTCATTTCCTGGTATGA-3Јand5Ј-CTTACTCC TTGGAGGCCATGTAG-3Ј. cDNA was synthesized from total RNA (Qiagen) using reverse transcriptase and a Superscript III kit (Invitrogen). The cDNA was synthesized from 1 g of total RNA. To standardize the reactions, GAPDH was amplified simultaneously. The change in reporter fluorescence in each reaction tube was monitored with an ABI 7300 Fast Real-Time PCR System (Applied Biosystems).
Gel zymography. Samples were prepared as described previously (Zhang and Gottschall, 1997; Mizoguchi et al., 2007a Mizoguchi et al., , 2007b . Briefly, brain tissues were homogenized in lysis buffer (50 mM Tris-HCl at pH 7.6, 150 mM NaCl, 5 mM CaCl 2 , 0.05% Briji 35, and 0.02% NaN 3 ) with 1% Triton X-100 and centrifuged at 12,000 ϫ g for 10 min to pellet insoluble materials. The protein concentration in the supernatant was determined using a Protein Assay Rapid Kit (Bio-Rad). The supernatant was incubated with gelatin-Sepharose 4B (GE Healthcare Biosciences), which had been previously washed three times with lysis buffer. The samples were subjected to constant shaking for 24 h at 4°C. After centrifugation at 500 ϫ g for 2 min, the pellet was resuspended in 500 l of lysis buffer and washed three times. The pellet was resuspended in 150 l of lysis buffer containing 10% dimethyl sulfoxide, shaken for 2 h, and used for assaying the gelatinase activities of MMP-2 and MMP-9.
The samples were subjected to electrophoresis in 10% SDS-polyacrylamide gels containing 0.1% gelatin under nonreducing conditions. Gels were washed twice for 30 min in 2.5% Triton X-100 to remove SDS, washed for 30 min in incubation buffer (50 mM Tris-HCl at pH 7.4, 5 mM CaCl 2 , 2 M ZnCl 2 , 200 mM NaCl, and 0.02% Briji 35) at 25 Ϯ 2°C, and further incubated for 24 h in the same buffer at 37°C. Gels were then stained for 3 h in Coomassie Blue (1% Coomassie Brilliant Blue G-250, 30% methanol, and 10% acetic acid) and destained in 40% methanol/7% acetic acid until clear bands of gelatinolysis appeared on the dark background. Total activity including pro-MMP was analyzed with an ATTO Densitograph Software Library Lane Analyzer (Atto Instruments).
Western blotting. ECM proteins were examined by Western blotting as described previously (Mizoguchi et al., 2004) . Protein concentrations were determined using a Protein Assay Rapid Kit (Wako Pure Chemicals). Tissue samples from the hippocampus were homogenized at 4°C in lysis buffer composed of 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 50 mM NaF, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 1 mM sodium orthovanadate, 0.1% SDS, 1% sodium deoxycholate, 0.5 mM dithiothreitol, 10 mM sodium pyrophosphate decahydrate, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 10 g/ml leupeptin, and 10 g/ml pepstatin. To analyze ECM proteins, 20 -40 g of protein were boiled in sample buffer (0.125 M Tris-HCl at pH 6.8, 2% SDS, 5% glycerol, 0.002% bromophenol blue, and 5% 2-mercaptoethanol), applied to a 10% polyacrylamide gel, transferred to a polyvinylidene difluoride membrane (Millipore) or a nitrocellulose membrane (GE Healthcare Biosciences), and blocked with 3% bovine serum albumin or 3% skim milk in Tris-buffered saline containing 0.1% Tween 20 for 2 h at 25 Ϯ 2°C. Membranes were then incubated with primary antibodies, including polyclonal rabbit anti-MMP-9 (1:1000 dilution; AB19016; Millipore Bioscience Research Reagents), anti-MMP-2 (1:1000 dilution; AB809; Millipore Bioscience Research Reagents), anti-BDNF (1:2000 dilution; SC-546; Santa Cruz Biotechnology), anti-laminin (1:2000 dilution, L9393; Sigma-Aldrich), anti-␤-dystroglycan (1:2000 dilution, NCL-␤-DG; Novocastra Laboratories), anti-neural cell adhesion molecular (NCAM, 1:2000 dilution, 556324; BD Biosciences), and anti-␤-actin (1: 2000, A5441; Sigma-Aldrich) antibodies. After washing, blots were incubated with horseradish peroxidase-conjugated anti-rabbit or mouse secondary antibodies at a 1:2000 dilution (Kirkegaard and Perry Laboratories). Immunoreactive materials on the membrane were detected using enhanced chemiluminescence Western blotting detection reagents (GE Healthcare Biosciences) and exposed to x-ray film. The band intensities of the film were analyzed using densitometry. Mature BDNF (rBDNF; SE-546, Enzo Life Sciences) and pro-BDNF (Alomone Labs) were used as positive controls on Western blots.
In situ zymography. Mice were intracardially perfused with cold saline before being frozen at Ϫ80°C using O.C.T. compound (Sakura Finetechnical). The brains were sectioned at a thickness of 20 m in a cryostat. We adapted a previously published in situ zymography method to localize net gelatinolytic activity in brain sections (Szklarczyk et al., 2002) . Unfixed sections were incubated for 24 h at 37°C in a humid dark chamber with reaction buffer containing 0.5 M Tris-HCl (pH 7.6), 1.5 M NaCl, 50 mM CaCl 2 , 2 mM NaN 3 , and 100 g/ml intramolecularly quenched FITC-labeled DQ-gelatin (Invitrogen). After incubation, sections were washed in PBS and mounted on slides. Samples were observed with a FITC filter, and the images were analyzed using an AXIOVISION 3.0 system (Carl Zeiss). Cleavage of the FITC moiety by tissue gelatinases results in fluorescence that is representative of net proteolytic activity. Sections incubated without DQ-gelatin were not fluorescent.
Double immunostaining. Polyclonal rabbit anti-MMP-9 antibodies (FITC or Rhod, 1:500 dilution; ab16306; Abcam), monoclonal mouse anti-neuron-specific nuclear antigen (NeuN) antibodies (FITC, 1:200 dilution; MAB377; Millipore Bioscience Research Reagents) and antiglial fibrillary acidic protein (GFAP) antibodies (Rhod, 1:3000 dilution; G3893; Sigma-Aldrich) served as primary antibodies. Affinity-purified FITC-conjugated goat anti-rabbit IgG and rhodamine-conjugated goat anti-mouse IgG were used as secondary antibodies. Samples were observed with an AXIOVISION 3.0 system (Carl Zeiss).
Statistical analysis. All data are expressed as means Ϯ SE. Statistical significance was determined using Student's t test for comparisons of two groups, one-way or two-way ANOVA for multigroup comparisons, and repeated-measures ANOVA. Bonferroni's test was used for post hoc comparison when the F value was significant (p Ͻ 0.05).
Results
Repeated administration of PTZ induced MMP-9 expression in the hippocampi of kindled and cognitively impaired mice Mice administered a single PTZ dose (20 -40 mg/kg) exhibited ear and facial twitching (Stage 1 seizure) or, at times, convulsive twitching axially through the body (Stage 2 seizure) (Fig. 1 A) . PTZ at a dose of 60 mg/kg induced a seizure characterized by tonic convulsion, jumping, and wild running (Stage 4 or 5). On the other hand, repeated administration of PTZ at a dose of 40 mg/kg produced chemical kindling, a phenotype reflected by a progressive increase in the seizure score (Stage 4 or 5) (Fig. 1 B; F (1,12) ϭ 32.0, p Ͻ 0.05, repeated-measures ANOVA). To assess learning and memory, we used a conditioned fear memory test that associated a contextual stimulus (conditioned experimental chamber stimulus) with an electric foot shook (unconditioned stimulus); the mice were subjected to the test 24 h after the final PTZ dose. Compared with control mice, kindled mice, but not mice treated with a single PTZ injection (60 mg/kg), showed less freezing behavior in response to the conditioned experimental chamber stimulus, indicating impaired hippocampal-dependent memory in the kindled mice ( Fig. 1C ; F (2,24) ϭ 6.77, p Ͻ 0.05, one-way ANOVA).
Repeated PTZ treatment increased MMP-9 expression in the hippocampus 2 h after the final PTZ dose (Fig. 2 B; p Ͻ 0.05, t test), and the increased MMP-9 levels were maintained until at least 24 h after the final dose ( Fig. 2C; p Ͻ 0.05, t test) . On the other hand, hippocampal MMP-9 levels were not affected in mice that showed convulsive seizures in response to a single PTZ dose of 60 mg/kg (Fig. 2 A; p Ͼ 0.05, t test) . Note that all of the groups showed similar hippocampal MMP-2 levels.
Net proteolytic activity in subregions of the hippocampus of MMP-2 (؊/؊) mice after repeated PTZ treatment We used in situ zymography to analyze changes in the spatial profile of hippocampal gelatinase activity following repeated PTZ treatment. Brain sections were incubated with gelatin conjugated to a quenched fluorescence dye, which, when cleaved by gelatinase, results in increased fluorescence. Previous experiments showed that this fluorescent signal was completely inhibited by the zinc chelator phenanthroline, a broad-spectrum MMP inhibitor, indicating that the fluorescence was associated with net MMP activity (Mizoguchi et al., 2007a (Mizoguchi et al., , 2009 ). Because we used MMP-2 (Ϫ/Ϫ) mice in this study, the increased fluorescence reflected MMP-9 activity. Two hours after the final PTZ dose (40 mg/kg), an intense signal was observed in the hippocampus (Fig.  2 Da,Dd). Net MMP-9 activity markedly increased in the DG (Fig. 2 Db,De) and CA3 (Fig. 2 Dc,Df ) of the hippocampus in the group repeatedly treated with PTZ compared with the salinetreated group.
Repeated PTZ treatment increased MMP-9 protein expression in the brain Next, we examined MMP-9 protein levels in the hippocampi of the kindled mice. Western blot analysis indicated that hippocampal levels of MMP-9 increased 2 h after repeated PTZ treatment compared with the level detected in the saline-treated group ( Fig.  3A; p Ͻ 0.05, t test) . MMP-2 protein levels were not affected by repeated PTZ treatment ( Fig. 3B; p Ͼ 0.05, t test) . Changes in MMP-9 (A) and MMP-2 (B) protein levels after repeated PTZ treatment in the mouse hippocampus. Mice were administered PTZ at least 11 times at a dose of 40 mg/kg and killed 24 h after the final dose. Control (Cont) mice were administered saline. Values are means Ϯ SE (n ϭ 5-6 for A; n ϭ 4 for B). *p Ͻ 0.05 versus control group. C-E, Representative photos of MMP-9 protein expression in mouse hippocampi after repeated treatment with PTZ. Mice were administered saline (Ca, Cc) or PTZ (Cb, Cd) at a dose of 40 mg/kg at least 11 times and killed 2 h after the final treatment. Double immunostaining of the hippocampus for MMP-9 (red, Da, Dd) and NeuN (green, Db, De), or MMP-9 (green, E) and GFAP (red, E) is shown. Scale bars, 100 m (scale bar in inset, 50 m).
To determine which cell types expressed MMP-9 following repeated PTZ treatment, we performed double immunostaining for MMP-9 and the neuronal marker NeuN (Fig. 3D) or the astroglial marker GFAP (Fig. 3E ). In the PTZ-treated group, stronger MMP-9-specific signals were observed in the DG and CA3 of the hippocampus compared with the saline-injected group (Fig. 3Cb ,Cd compared with 3Ca,Cc). Most immunoreactivity in the control and PTZ-treated groups was observed in NeuN-positive cells (Fig. 3C ,Dc,Df ), suggesting that MMP-9 was expressed in neurons. Immunosignals were also observed in GFAP-positive cells in the hippocampus (Fig. 3E) . These results indicate that repeated PTZ treatment induces MMP-9 expression in both neuronal and glial cells in the hippocampus.
Diazepam inhibited the kindled seizures and MMP-9 expression induced by repeated PTZ treatment
We examined whether diazepam, which is used to treat epilepsy, inhibited hippocampal MMP-9 expression in kindled mice. Pretreatment with diazepam significantly suppressed the development of PTZ-induced kindled seizure ( Fig. 4A; F (1,10) ϭ 59.6, p Ͻ 0.05, repeated two-way ANOVA), and inhibited MMP-9 expression in the hippocampi of kindled mice ( Fig. 4B; F (2,18) ϭ 8.50, p Ͻ 0.05, one-way ANOVA). Diazepam had little effect on MMP-2 expression in the hippocampus.
Pretreatment with MK-801 inhibited PTZ-induced kindled seizure and hippocampal MMP-9 expression
Pretreating rats with NMDA receptor antagonists at doses that do not have a marked anticonvulsant effect reportedly prevents epileptogenesis in kindling, pilocarpine, and kainate models of limbic seizure (Ormandy et al., 1989; Stafstrom et al., 1997) . Interestingly, MMP-9 expression is induced via NMDA receptor signaling (Meighan et al., 2006; Nagy et al., 2006; Tian et al., 2007) . Therefore, we investigated the effects of MK-801 on PTZ-induced increases in MMP-9 expression and kindled seizure. Pretreatment with MK-801 significantly suppressed the development of kindling ( Fig. 5A ; F (1,9) ϭ 14.3, p Ͻ 0.05, repeated two-way ANOVA) and inhibited MMP-9 expression in the hippocampus ( Fig. 5B; F (2,9) ϭ 8.60, p Ͻ 0.05, one-way ANOVA), suggesting that NMDA receptors are involved in these processes in vivo.
MMP-9 contributed to PTZ-induced development of kindled seizure
We investigated the role for MMP-9 in PTZ-induced kindled seizure using MMP-9 (Ϫ/Ϫ) mice. No difference in the severity of tonic seizure induced by single PTZ treatment (35-60 mg/kg) was observed between wild-type and MMP-9 (Ϫ/Ϫ) mice (Fig. 6A ). As shown in Figure 6B , repeated PTZ treatment at a dose of 35 mg/kg induced kindled seizure in wild-type mice. Under these conditions, PTZtreated MMP-9 (Ϫ/Ϫ) mice showed a marked delay in development of kindling, although progression of kindled seizure was eventually observed ( Fig. 6B; F (1,24) ϭ 6.11, p Ͻ 0.05, repeated two-way ANOVA). These results demonstrate that deletion of the MMP-9 gene attenuated PTZ-induced kindled seizure.
Altered BDNF maturation in the hippocampi of kindled mice BDNF is associated with mossy fiber sprouting in the hippocampus. Extracellular BDNF stimulates TrkB receptors in the hilar segment of mossy fibers, inducing axonal branching and potentially establishing hyperexcitable dentate circuits (Koyama et al., 2004) . Notably, BDNF is a substrate of MMP (Lee et al., 2001; Ethell and Ethell, 2007) . We used Western blotting to confirm that mature BDNF formed when recombinant pro-BDNF was incubated with recombinant MMP-9 in zymography incubation buffer for 20 h at 37°C (data not shown).
Repeated PTZ treatment increased protein and mRNA levels of BDNF in the hippocampi of kindled mice as described below, whereas protein levels of other substrates for MMP, such as laminin (Gu et al., 2005) , ␤-dystroglycan (Michaluk et al., 2007) , and NCAM (Hübschmann et al., 2005) , did not change (Table 1 ). In fully kindled 
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(Ϫ/Ϫ) mice that received 11 PTZ injections, BDNF mRNA levels in the hippocampus were significantly elevated compared with wild-type mice 6 h after the final PTZ dose ( Fig. 7A; gene, F (1,16) (Ϫ/Ϫ) mice, with no significant differences between the two groups ( Fig. 7B,C (Ϫ/Ϫ) mice revealed no significant differences in mature BDNF levels or the ratio of mature BDNF to pro-BDNF (p Ͼ 0.05).
Interestingly, on Day 5 of repeated PTZ treatments-at which point, kindling had not yet fully developed (Fig. 6B )-mature BDNF protein levels increased in the hippocampi of wild-type mice (p Ͻ 0.05), but not MMP-9 (Ϫ/Ϫ) mice ( Fig. 7D,E ; drug treatment, F (1,16) ϭ 48.2, p Ͻ 0.05; gene, F (1,16) ϭ 23.3, p Ͻ 0.05; interaction, F (1,16) ϭ 16.5, p Ͻ 0.05). The ratio of mature BDNF to pro-BDNF increased in kindled wildtype mice (p Ͻ 0.05), with significant differences between PTZ-treated wild-type mice and MMP-9 (Ϫ/Ϫ) mice ( Fig. 7E ; drug treatment, F (1,16) ϭ 13.5, p Ͻ 0.05; gene, F (1,16) ϭ 12.9, p Ͻ 0.05; interaction, F (1,16) ϭ 5.98, p Ͻ 0.05). No differences were noted between saline-treated wild-type mice and saline-treated MMP-9 (Ϫ/Ϫ) mice in mature BDNF levels or the ratio of mature BDNF to pro-BDNF (p Ͼ 0.05). Similar changes in the levels of mature BDNF were observed when BDNF levels were analyzed 24 h after the final PTZ treatment (data not shown). These results suggest that MMP-9 increases mature BDNF levels in response to repeated PTZ injections, which may contribute to kindling development.
Effects of TrkB-Fc and pro-BDNF on kindling development in MMP-9
(؊/؊) mice To further examine the relationship between MMP-9 and pro-BDNF maturation in PTZ-induced kindling, we investigated effects of TrkB-Fc-a BDNF scavenger (Rex et al., 2007; Zhou et al., 2010 Zhou et al., , 2011 -and pro-BDNF on the development of kindling in MMP-9 (Ϫ/Ϫ) mice. In a preliminary study, implanting guide cannula into the right ventricle or hippocampal DG increased the sensitivity of mice to PTZ. Accordingly, the PTZ dose was reduced to 25 mg/kg, which caused the animals to exhibit seizures with a score of 1.
Compared with wild-type mice, PTZ-treated MMP-9
(Ϫ/Ϫ) mice that received intraventricular injections of IgG 1 -Fc showed a marked delay in the development of kindling (Fig.   Figure 7 . BDNFmRNAandmatureBDNFproteinexpressioninthemousehippocampus.A-C,MicewereadministeredPTZ11timesat adoseof35mg/kgandkilled6hafterthefinaldose.Controlanimalsaresaline-treatedwild-typemice.ValuesaremeansϮSE(nϭ5-6). *p Ͻ 0.05 versus the saline-treated group. B, D, Representative images of Western blots of samples obtained after 11 or 5 PTZ doses, respectively. Mature BDNF (rBDNF) was used as a positive control. WT: wild-type mice. KO: MMP-9 (Ϫ/Ϫ) mice. D, E, Mice were administered PTZ five times at a dose of 35 mg/kg and killed 6 h after the final dose. Control animals are saline-treated wild-type mice. Values are means Ϯ SE (n ϭ 5). *p Ͻ 0.05 versus saline-treated group. #p Ͻ 0.05 versus wild-type mice (PTZ). Table 1 . No changes in laminin, ␤-dystroglycan, and NCAM protein after repeated PTZ treatment in the hippocampus of mice laminin (n ϭ 4) chain  30 kDa  43 kDa  120 kDa  140 kDa  180 kDa Control 100 Ϯ 9.0 100 Ϯ 9.6 100 Ϯ 7.1 100 Ϯ 6.3 100 Ϯ 6.4 100 Ϯ 7.8 100 Ϯ 6.1 Repeated PTZ 79.2 Ϯ 2.6 87.4 Ϯ 4.7 82.0 Ϯ 8.5 97.9 Ϯ 6.4 80.9 Ϯ 9.6 89.5 Ϯ 6.9 84.4 Ϯ 6.9
8 A, B; F (1,16) ϭ 4.73, based on repeated two-way ANOVA). Pretreating the right ventricle with TrkB-Fc significantly suppressed the development of kindling in wild-type mice (Fig. 8 A; group, F (1,18) ϭ 6.57, p Ͻ 0.05; stimulation, F (7,126) ϭ 10.45, p Ͻ 0.05; interaction, F (7,126) ϭ 1.07, p Ͼ 0.05, based on repeated two-way ANOVA), but had no effect in MMP-9 (Ϫ/Ϫ) mice (Fig. 8 B;  group, F (1,14) ϭ 0.10, p Ͼ 0.05; stimulation, F (7, 98) ϭ 10.7, p Ͻ 0.05; interaction, F (6,84) ϭ 0.45, p Ͼ 0.05, based on repeated two-way ANOVA). On the other hand, bilateral microinjections of pro-BDNF into the hippocampal DG before each PTZ treatment significantly enhanced kindling development in wild-type mice ( Fig. 8C ; group, F (1,16) ϭ 6.50, p Ͻ 0.05; stimulation, F (6,96) ϭ 25.1, p Ͻ 0.05; interaction, F (6,96) ϭ 0.71, p Ͻ 0.05, based on repeated two-way ANOVA), whereas the same treatment did not produce these effects in MMP-9 (Ϫ/Ϫ) mice (Fig. 8 D; group, F (1,12) ϭ 2.27, p Ͼ 0.05; stimulation, F (6,72) ϭ 11.26, p Ͻ 0.05; interaction, F (6,72) ϭ 0.34, p Ͼ 0.05, based on repeated two-way ANOVA). These results suggest that MMP-9 contributes to the development of PTZ-induced kindling seizure, possibly by converting pro-BDNF to mature BDNF in the hippocampus.
Discussion
In the present study, we demonstrated that kindling progression results in persistently increased MMP-9 protein expression and activity in the mouse hippocampus, whereas acute convulsion had little effect on this enzyme. Recent studies have linked MMPs to various pathologic conditions in the central nervous system, including ischemia, multiple sclerosis, Parkinson's disease, malignant glioma, Alzheimer's disease, and epilepsy. Interestingly, some evidence suggests that, in addition to its known extracellular role in macromolecule degradation, MMP may mediate apoptotic and/or necrotic cell death (Jourquin et al., 2003; Kim et al., 2009 ) and synaptic plasticity (Tian et al., 2007; Wilczynski et al., 2008; Takács et al., 2010) . The gelatinases MMP-2 and MMP-9 are initially expressed as inactive proenzymes that are cleaved to their active forms after they are released from cells (Van den Steen et al., 2002) , allowing these proteases to regulate the levels of extracellular substrates. Our data showed that repeated treatment with PTZ led to kindling and cognitive impairment, which was accompanied by increased MMP-9 expression in the hippocampus. Additionally, we demonstrated that MMP-9 was expressed in hippocampal neuronal and glial cells in the kindled mice.
A previous study revealed that MMP-9 mRNA levels increased in response to neuronal depolarization in the rat hippocampus (Rylski et al., 2009) . After seizure in kainic acid-treated rats, MMP-9 mRNA is transported to dendrites and synapses in the hippocampal DG . Our findings are consistent with these previous reports, suggesting that MMP-9 from astrocytes and/or neurons may contribute to PTZ-induced epileptogenesis and kindling seizure. On the other hand, some of our findings are not consistent with previous reports. For instance, a prominent increase in MMP-9 mRNA levels was observed in rats 2 h after a single 50 mg/kg PTZ dose (Rylski et al., 2009) , and MMP-9 activity increased as early as 5 min after bicuculline treatment in mouse cortical cultures (Michaluk et al., 2007) . More detailed examination of temporal changes and species differences in MMP-9 expression after single and repeated PTZ injection may help explain these discrepant results.
Pretreatment with MK-801 inhibited the PTZ-induced increase in MMP-9 expression and kindling, indicating that these events are associated with activation of NMDA receptors in this model (Fig. 5) . In fact, an NMDA receptor antagonist completely prevented PTZ-induced convulsions and kindling (Giorgi et al., 1991) , and excessive levels of synaptic glutamate and persistent influx of Ca 2ϩ through NMDA receptors are considered major causes of epileptogenesis . In addition, the expression and activity of MMP-9 depend on NMDA receptor activation and are associated with LTP development (Meighan et al., 2006; Nagy et al., 2006) . Activation of NMDA receptors leads to MMP-mediated modification of cell adhesion molecules and the development of dendritic spines (Tian et al., 2007) . Our results suggest that MMP-9 expression and activity are regulated by repetitive activation of NMDA receptors, which may result in remodeling of neuronal circuits, epileptogenesis, and the development of kindling.
Dendritic spine morphology and synaptic potentiation are dynamically modulated by ECM proteins and cell-surface proteins with which they interact. This has led to the idea that ECM remodeling has an important role in synaptic plasticity. Indeed, evidence suggests that MMP-9 expression is upregulated and the protein becomes proteolytically active during the maintenance phase of LTP at CA3-CA1 synapses in the hippocampus (Nagy et al., 2006; Bozdagi et al., 2007) . Similar findings have been recently reported for the rat prefrontal cortex (Okulski et al., 2007) . These reports suggest a role for MMP-9 in neuronal plasticity, a concept supported by our findings in PTZ-induced kindled seizure. Marked suppression of the progression of kindled seizure induced by repeated PTZ treatment was observed in MMP-9 (Ϫ/Ϫ) mice compared with wild-type mice (Fig. 6 B) . We showed that mossy fiber sprouting induced by repeated PTZ treatment was reduced in (Ϫ/Ϫ) mice compared with wild-type mice whose strain were FVB/N (data not shown), suggesting that increased hippocampal MMP-9 activity is associated with the sprouting of mossy fibers. These observations agree with recent findings showing that the synaptic pool of MMP-9 is critical for the mechanisms that underlie seizure development (Wilczynski et al., 2008) . Similarly, degradation of laminin by tissue plasminogen activator (tPA) directly affects the dynamics of dendritic spine development (Oray et al., 2004) , and tPA/plasmin regulates seizure-induced hippocampal mossy fiber outgrowth via a proteoglycan substrate (Wu et al., 2000) . Accordingly, extracellular proteolytic systems, including MMP-9 and tPA, may play critical roles in aberrant synaptogenesis associated with epileptic seizure. PTZ-induced kindling may be aggravated through synaptic transformation, including mossy fiber sprouting induced by prolonged MMP-9 activation.
BDNF, a member of the neurotrophin family, plays an important role in the survival, differentiation, and growth of many types of neurons (Chao, 2003) . BDNF has also been implicated as a potent morphoregulator that controls axon branching and activity-dependent refinement of synapses (Cabelli et al., 1995; Horch et al., 1999) . Extracellular BDNF stimulates TrkB receptors on the hilar segment of the mossy fiber to induce axonal branching, which may create hyperexcitable dentate circuits (Koyama et al., 2004) . We previously showed that BDNF contributes to nitric oxide-dependent plastic changes in neuronal excitability and epileptogenesis during kindling induced by PTZ (Han et al., 2000) . These previous studies suggest that BDNF plays an etiologic role in epileptogenesis and kindled seizure. A recent study showed that high-frequency neuronal activity controls the ratio of extracellular pro-BDNF to mature BDNF by regulating the secretion of extracellular proteases (Nagappan et al., 2009 ). Of particular note for the present results, proforms of neurotrophin are cleaved and activated by MMP (Lee et al., 2001; Sternlicht and Werb, 2001; Ethell and Ethell, 2007) , and MMP-9 converts pro-BDNF to mature BDNF, resulting in TrkB activation (Hwang et al., 2005; Ethell and Ethell, 2007) .
We have demonstrated that BDNF expression, and in particular levels of mature BDNF, increased in the hippocampus in response to PTZ-induced kindling. This finding agrees with a previous report showing that levels of mature BDNF increased after status epilepticus in rats, whereas pro-BDNF levels did not change until 72 h after status epilepticus (Unsain et al., 2008) . Importantly, (Ϫ/Ϫ) mice showed reduced levels of mature BDNF during the early stage of kindling, which may explain slower kindling development in the mutant animals. During the later kindling stage, however, mature BDNF levels were similar in MMP-9 (Ϫ/Ϫ) and wild-type mice. Our findings suggest that MMP-9 plays a role in kindling development by converting pro-BDNF to mature BDNF in the hippocampus, whereas other factors mediate BDNF maturation during the later kindling stage. This may explain why the seizure response curves for MMP-9 (Ϫ/Ϫ) and wild-type mice differ more at the early stage than at the later stage of kindling.
We also examined whether experimentally decreasing mature BDNF levels using the BDNF scavenger TrkB-Fc attenuated kindling or increasing pro-BDNF levels enhanced kindling in wildtype mice. In the experiment of pro-BDNF injection, kindling development was not delayed in (Ϫ/Ϫ) mice following intrahippocampal PBS injections, whereas a significant delay was observed in (Ϫ/Ϫ) mice following intraventricular injections of IgG 1 -Fc. The mechanisms underlying these findings are unclear, but may result from tissue damage caused by bilateral implantation of guide cannulae into the hippocampus. Under these conditions, the effects of TrkB-FC and pro-BDNF injections on PTZ-induced kindling were observed only in wild-type mice, but not MMP-9
(Ϫ/Ϫ) mice. These results likely reflect a relationship between MMP-9 expression and mature BDNF levels in the development of PTZ-induced kindling.
In conclusion, the present findings highlight the contribution of neural/glial MMP-9 to epileptogenesis via its activity on extracellular macromolecules, such as BDNF. Importantly, selective MMP-9 inhibitors may provide neuroprotective effects in patients with epilepsy.
